Copyright
©The Author(s) 2015.
World J Transplant. Dec 24, 2015; 5(4): 310-319
Published online Dec 24, 2015. doi: 10.5500/wjt.v5.i4.310
Published online Dec 24, 2015. doi: 10.5500/wjt.v5.i4.310
Table 5 Reasons for everolimus withdrawal
| Drug withdrawal | n | % total patients that discontinue treatment (95%CI) (n = 44) | % total evaluable patients (95%CI) (n = 222) |
| Oedemas | 13 | 29.5% (16.1-43.0) | 5.9% (2.8-9.8) |
| Gastrointestinal disorders | 8 | 18.2% (6.8-29.6) | 3.6% (1.2-6.1) |
| Bone marrow suppression | 4 | 9.1% (0.6-17.6) | 1.8% (0.1-3.6) |
| Pneumonitis | 4 | 9.1% (0.6-17.6) | 1.8% (0.1-3.6) |
| Skin disorders | 2 | 4.6% (0.1-10.7) | 0.9% (0.1-9.5) |
| Others | 14 | 31.8% (18.1-45.6) | 6.3% (3.1-9.5) |
- Citation: Manito N, Delgado JF, Crespo-Leiro MG, Arizón JM, Segovia J, González-Vílchez F, Mirabet S, Lage E, Pascual-Figal D, Díaz B, Palomo J, Rábago G, Sanz M, Blasco T, Roig E. Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients. World J Transplant 2015; 5(4): 310-319
- URL: https://www.wjgnet.com/2220-3230/full/v5/i4/310.htm
- DOI: https://dx.doi.org/10.5500/wjt.v5.i4.310